Gastrointestinal (GI) cancers represent a significant global health burden with complex biological behaviors and ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital’s Memory and Aging ...

Background Infectious agents such as SARS-CoV-2 require strategies to contain outbreaks, particularly in hospitals where the ...

Keymed Biosciences Inc. (HKEX: 02162) ('Keymed' or the 'Company') today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...

The Trump administration this week decimated HIV prevention programs across government health agencies after terminating ...

Demolition works as part of preparations for the second phase of the Liverpool Health and Academic Precinct (LHAP) redevelopment of Liverpool Hospital will begin this month.

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier ...